Pentixapharm Holding AG

For #Investors and #Media We are pleased to announce that the US National Cancer Institute (NCI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) have initiated an advanced clinical trial with Pentixapharm's Ga68-PentixaFor. This FDA-endorsed phase II study aims to explore the efficacy of Ga68-PentixaFor in identifying functional adrenal tumors through PET imaging, focusing on hormone-secreting adenomas in primary aldosteronism (PA) and Cushing’s syndrome. Read the full release here: https://lnkd.in/di5Pb43K #radiopharmaceuticals #PentixaFor #PentixaTher #CXCR4 #CapitalMarkets #Biotech #NCI

For #Investors and #Media Pentixapharm is looking forward to the 37th Annual Congress of the European Association of Nuclear Medicine (EANM), which takes place in Hamburg from 19–23 October 2024. 𝗬𝗼𝘂 𝗰𝗮𝗻 𝗳𝗶𝗻𝗱 𝘂𝘀 𝗶𝗻 𝗵𝗮𝗹𝗹 𝗛 𝗮𝘁 𝗯𝗼𝗼𝘁𝗵 𝗛𝟭𝟵. Our CXCR4-targeting compound is the subject of 17 abstract presentations that will take place over the next few days, highlighting the many applications of CXCR4 and the work of our collaborators at one of the largest gatherings of nuclear medicine professionals globally. You can read the full release here: https://lnkd.in/d9eXgEVY #radiopharmaceuticals #eanm #eanm2024 #PentixaFor #PentixaTher #CXCR4 #CapitalMarkets #Biotech

For #Investors and #Media Today, we are excited to share that Pentixapharm's lead candidate, #PentixaFor, has been granted PRIME status by the European Medicines Agency (EMA). This important milestone provides early and proactive support for the development of our novel radiodiagnostic and the possibility of an accelerated approval. Pentixapharm is currently preparing a Phase III pivotal study to obtain marketing authorization for PentixaFor in primary aldosteronism (PA) that will start in 2025. You can read the full release here: https://lnkd.in/dGcvKKhc #Radiopharmaceuticals #PentixaFor #PentixaTher #EMA #CXCR4 #CapitalMarkets #Biotech

👋 𝗙𝗮𝗿𝗲𝘄𝗲𝗹𝗹 𝗮𝗻𝗱 𝗯𝗲𝘀𝘁 𝗼𝗳 𝗹𝘂𝗰𝗸, Pentixapharm AG! Today, we say goodbye to Pentixapharm, which is now 𝘁𝗵𝗿𝗶𝘃𝗶𝗻𝗴 𝗮𝘀 𝗮𝗻 𝗶𝗻𝗱𝗲𝗽𝗲𝗻𝗱𝗲𝗻𝘁 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 following its 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝗜𝗣𝗢 𝘆𝗲𝘀𝘁𝗲𝗿𝗱𝗮𝘆 on October 3rd. Having been part of the 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 𝗳𝗮𝗺𝗶𝗹𝘆, we are proud to have supported their incredible journey in 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀, and we look forward to their future success! 💬 "As Pentixapharm embarks on this 𝗻𝗲𝘄 𝗮𝗱𝘃𝗲𝗻𝘁𝘂𝗿𝗲, we take pride in the 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀 𝘄𝗲’𝘃𝗲 𝗮𝗰𝗵𝗶𝗲𝘃𝗲𝗱 together. Their success is a testament to the 𝗽𝗼𝘄𝗲𝗿 𝗼𝗳 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻,” says Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. 🤝 This marks a 𝗻𝗲𝘄 𝗰𝗵𝗮𝗽𝘁𝗲𝗿, but our 𝗰𝗼𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝘀𝗵𝗮𝗿𝗲𝗱 𝗰𝗼𝗺𝗺𝗶𝘁𝗺𝗲𝗻𝘁 to pushing the boundaries of precision healthcare will 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝘁𝗼 𝗶𝗻𝘀𝗽𝗶𝗿𝗲. 𝗪𝗶𝘀𝗵𝗶𝗻𝗴 𝗣𝗲𝗻𝘁𝗶𝘅𝗮𝗽𝗵𝗮𝗿𝗺 𝗴𝗿𝗲𝗮𝘁 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 𝗶𝗻 𝘁𝗵𝗲 𝘆𝗲𝗮𝗿𝘀 𝗮𝗵𝗲𝗮𝗱! 🚀 #Radiopharmaceuticals #NuclearMedicine #SpinOff #Investors #ContributingToSavingLives

Today, we are thrilled to announce that #Pentixapharm Holding AG has successfully completed its #IPO on the Prime Standard of the Börse Frankfurt under the ticker symbol PTP. The first trading price was EUR 5.10 per share, marking a significant milestone in our journey as an independent, publicly listed company. With a strong market capitalization at the start of trading of EUR 126.5 million and secured funding of approximately EUR 19.9 million from the IPO, alongside an additional EUR 18.5 million from a convertible bond issuance, we are well-positioned to accelerate the development of our innovative radiopharmaceutical pipeline. You can read the full release here: https://lnkd.in/eyQN7rrd #IPO #Radiopharmaceuticals #CXCR4 #PentixaFor #PentixaTher #CapitalMarkets #Biotech Copyright: Deutsche Börse AG

For #Investors and #Media   Today, we are excited to announce that we set the final placement price for #Pentixapharm Holding AG’s #IPO at EUR 5.10 per share, with all 3.9 million offer shares successfully placed.   Based on the final placement price, the total gross proceeds to us amount to EUR 19.9 million, with an expected free float of 61.6%, ensuring liquidity and opportunities for our investors.   Our shares will begin trading on the Prime Standard of the Börse Frankfurt on October 3, 2024.   You can read the full release here: https://lnkd.in/eHtcVJV4 #Radiopharmaceuticals #CXCR4 #PentixaTher #PentixaFor #CapitalMarkets #Biotech

A powerful partnership with Pentixapharm AG on display at key investor conferences before their IPO! 🤝 In the last two days, Dr. Harald Hasselmann, CEO of Eckert & Ziegler, and Patrik Kehler, CSO of Pentixapharm, attended both the Baader Bank AG 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 and the 𝗚𝗲𝗿𝗺𝗮𝗻 𝗖𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲, organized by Berenberg and Goldman Sachs. These pivotal events mark the final joint appearance of Eckert & Ziegler and its subsidiary Pentixapharm before the already initiated spin-off. 📈 𝗣𝗲𝗻𝘁𝗶𝘅𝗮𝗽𝗵𝗮𝗿𝗺 𝗶𝘀 𝗴𝗲𝗮𝗿𝗶𝗻𝗴 𝘂𝗽 𝗳𝗼𝗿 𝗶𝘁𝘀 𝗜𝗣𝗢 on the Frankfurt Stock Exchange, with the first trading day scheduled for 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟯𝗿𝗱. While we have a 𝘀𝗵𝗮𝗿𝗲𝗱 𝗰𝗼𝗺𝗺𝗶𝘁𝗺𝗲𝗻𝘁 𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 in radiopharmaceuticals and continuing to shape the future of cancer therapy, this step allows both companies to 𝗶𝗻𝗱𝗲𝗽𝗲𝗻𝗱𝗲𝗻𝘁𝗹𝘆 𝘁𝗮𝗿𝗴𝗲𝘁 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 according to their individual markets. 💬 Dr. Hasselmann emphasized: “Our collaboration with Pentixapharm has been instrumental in 𝗱𝗿𝗶𝘃𝗶𝗻𝗴 𝗳𝗼𝗿𝘄𝗮𝗿𝗱 𝗰𝘂𝘁𝘁𝗶𝗻𝗴-𝗲𝗱𝗴𝗲 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 in nuclear medicine. We look forward to seeing them 𝘁𝗵𝗿𝗶𝘃𝗲 𝗮𝘀 𝗮𝗻 𝗶𝗻𝗱𝗲𝗽𝗲𝗻𝗱𝗲𝗻𝘁 𝗰𝗼𝗺𝗽𝗮𝗻𝘆.” #ContributingToSavingLives #Radiopharmaceuticals #NuclearMedicine #IPO #Investors

For #Investors and #Media Today, we are excited to announce that #Pentixapharm Holding AG has officially kicked off the #IPO process on the Prime Standard of the Börse Frankfurt. The public offering comprises up to 3.9 million new shares at a price range of EUR 4.70 to EUR 6.00 per share. The proceeds from the #IPO will be used to advance our innovative pipeline in the rapidly growing field of radioligand therapies. The subscription period for institutional and retail investors will open on September 24, 2024, and is expected to close on October 1, 2024. With a high anticipated free float of over 60%, our first trading day is set for October 3, 2024. You can read the full release here: https://lnkd.in/esKzFRqf #Radiopharmaceuticals #CXCR4 #PentixaTher #PentixaFor #CapitalMarkets #Biotech

Our Co-Founder and Chairman of the Supervisory Board, Andreas Eckert this week had the chance to talk to Stephen Hansen about #Pentixapharm and our recently announced IPO plans.    A successful Frankfurt debut would mark just the beginning of Pentixapharm’s journey in the booming radiopharma space. With a solid strategy, including expansion into high-potential areas like primary aldosteronism, we are well positioned in the biotech landscape.    Read the full BioCentury Inc. Inc. article to learn more about Pentixapharm’s promising pipeline, including our Phase III programs with #PentixaFor and #PentixaTher (subscription required). 👇 https://lnkd.in/e-UF7vyB #Biotech #Radiopharmaceuticals #IPO #FrankfurtStockExchange

It was a pleasure to welcome Brad Loncar from #BiotechTV to our Pentixapharm offices in Berlin. Andreas Eckert, our Co-Founder and Chairman of the Supervisory Board, discussed the radiopharmaceutical market, the production of #isotopes and #Pentixapharm’s novel theranostic approach. Watch the full interview to learn more about his entrepreneurial journey, the future of radiopharmaceuticals and the impact of this technology on cancer treatments and beyond: https://lnkd.in/g-UKrvY5